The Food and Drug Administration (FDA) conducted an inspection of the Central Pennsylvania Blood Bank in Ephrata on March 11, focusing on blood and blood products, as indicated by data published on the FDA’s website.
The inspection report showed that no corrective actions were required for the organization’s management practices.
The FDA regularly inspects facilities nationwide to ensure workplaces and their products comply with relevant laws and regulations aimed at supporting public health. The outcomes of these inspections are made available to the public.
According to the FDA’s website, the agency is primarily tasked with overseeing the safety and quality of human and veterinary drugs, biological products, medical devices, and tobacco products.
Information for this article comes from the U.S. Food and Drug Administration. The source data is accessible here.
